|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
Inotek Pharmaceuticals
Acquired by the Bausch Health Companies
|
|
gptkbp:acquisition_year
|
gptkb:2018
|
|
gptkbp:advocacy
|
gptkb:Yes
|
|
gptkbp:annual_report
|
gptkb:Yes
|
|
gptkbp:business_model
|
gptkb:Research_and_development
gptkb:Partnerships
Commercialization
Focused on specialty pharmaceuticals
|
|
gptkbp:ceo
|
V. Paul di Giovanni
V. Paul Wright
|
|
gptkbp:clinical_milestones
|
Achieved several
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Asia
gptkb:Canada
gptkb:United_States
gptkb:Yes
Completed
Ongoing
Pending
Phase 1
Phase 2
Phase 3 trials
Recruiting
Published in peer-reviewed journals
Ocular hypertension
Open-angle glaucoma
Ocular therapeutics
Intraocular pressure reduction
Not yet recruiting
|
|
gptkbp:collaboration
|
gptkb:Duke_University
gptkb:University_of_North_Carolina
With academic institutions
|
|
gptkbp:collaborations
|
With leading universities
|
|
gptkbp:community_engagement
|
gptkb:Yes
|
|
gptkbp:competitive_landscape
|
gptkb:Dynamic
|
|
gptkbp:conducts_research_on
|
Dr. David A. Stump
|
|
gptkbp:conflict
|
gptkb:Yes
|
|
gptkbp:displacement
|
gptkb:Yes
|
|
gptkbp:employees
|
200+
Over 200
|
|
gptkbp:financial_performance
|
Publicly reported
|
|
gptkbp:financial_reports
|
Annual report 2020
Quarterly report Q1 2021
Quarterly report Q2 2021
Quarterly report Q3 2021
Quarterly report Q4 2021
|
|
gptkbp:financials
|
Strong investor support
|
|
gptkbp:focus
|
gptkb:Ophthalmology
|
|
gptkbp:founded
|
gptkb:2008
|
|
gptkbp:founder
|
David A. Hollander
D. Michael T. Mc Ginnis
|
|
gptkbp:future_prospects
|
Positive
|
|
gptkbp:grants
|
gptkb:National_Eye_Institute
|
|
gptkbp:has_advisory_board
|
gptkb:Yes
|
|
gptkbp:headquarters
|
gptkb:Durham,_North_Carolina
|
|
gptkbp:healthcare
|
gptkb:2018
gptkb:Yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aerie Pharmaceuticals
|
|
gptkbp:instruction_set
|
Diverse
Multiple candidates in development
|
|
gptkbp:invention
|
Multiple patents granted
Netarsudil formulation
Ocular drug delivery
Roclatan formulation
|
|
gptkbp:investment
|
gptkb:Vanguard_Group
gptkb:Black_Rock
gptkb:Yes
Various venture capital firms
Regularly conducted
In research and development
|
|
gptkbp:investment_strategy
|
Varies with market conditions
|
|
gptkbp:ipo
|
gptkb:2017
|
|
gptkbp:market_cap
|
Approximately $1 billion (2021)
$1 billion (2020)
|
|
gptkbp:market_launch
|
Strategic
Rhopressa (2018)
Roclatan (2019)
|
|
gptkbp:marketing_strategy
|
Innovative approaches
Focused on niche markets
|
|
gptkbp:partnership
|
gptkb:Santen_Pharmaceutical
gptkb:Yes
|
|
gptkbp:partnerships
|
With healthcare providers
With other biotech firms
|
|
gptkbp:product
|
Roclatan
Rhopressa
Netarsudil
Latanoprost
|
|
gptkbp:publications
|
gptkb:Yes
|
|
gptkbp:reach
|
gptkb:Yes
|
|
gptkbp:regulatory_compliance
|
gptkb:Yes
Multiple products approved
|
|
gptkbp:research_areas
|
Glaucoma
Eye diseases
In various stages of development
|
|
gptkbp:research_focus
|
Glaucoma
Innovative therapies
|
|
gptkbp:revenue
|
$100 million (2020)
|
|
gptkbp:social_responsibility
|
gptkb:Yes
|
|
gptkbp:stock_exchange
|
gptkb:Yes
|
|
gptkbp:stock_symbol
|
AERI
|
|
gptkbp:subsidiary
|
Aerie Pharma, Inc.
|
|
gptkbp:team
|
Experienced professionals in pharma
|
|
gptkbp:therapeutic_innovations
|
gptkb:Yes
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.aeriepharma.com
|
|
gptkbp:bfsParent
|
gptkb:M._Scott_Whitcup
|
|
gptkbp:bfsLayer
|
7
|